Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BNGO Stock Forecast 2026-2027
$1.55
Current Price
$15.00M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BNGO Price Targets
+416.1%
To High Target of $8.00
+383.9%
To Median Target of $7.50
+351.6%
To Low Target of $7.00
BNGO Price Momentum
-3.1%
1 Week Change
+0.6%
1 Month Change
-87.1%
1 Year Change
+1.3%
Year-to-Date Change
-90.1%
From 52W High of $15.60
+6.9%
From 52W Low of $1.45
📊 TOP ANALYST CALLS
Did BNGO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BioNano is one of their latest high-conviction picks.
Latest BNGO Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, BNGO has a bullish consensus with a median price target of $7.50 (ranging from $7.00 to $8.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.55, the median forecast implies a 383.9% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason McCarthy at Maxim Group, projecting a 416.1% upside. Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 351.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BNGO Analyst Ratings
2
Buy
0
Hold
0
Sell
BNGO Price Target Range
Low
$7.00
Average
$7.50
High
$8.00
Current: $1.55
Latest BNGO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BNGO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 24, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $7.00 |
| Aug 18, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $11.00 |
| May 20, 2025 | Maxim Group | Jason McCarthy | Buy | Upgrade | $8.00 |
| Apr 9, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $10.00 |
| Apr 2, 2025 | Scotiabank | Sung Ji Nam | Sector Perform | Maintains | $4.00 |
| Nov 15, 2024 | Ladenburg Thalmann | Jeff Cohen | Neutral | Downgrade | $N/A |
| Sep 10, 2024 | BTIG | Mark Massaro | Neutral | Downgrade | $N/A |
| Aug 28, 2024 | Scotiabank | Sung Ji Nam | Sector Perform | Downgrade | $1.00 |
| May 16, 2024 | BTIG | Mark Massaro | Buy | Maintains | $2.00 |
| Mar 7, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $6.00 |
| Nov 13, 2023 | Maxim Group | Jason McCarthy | Hold | Downgrade | $N/A |
| Aug 10, 2023 | BTIG | Mark Massaro | Buy | Maintains | $10.00 |
| Jun 9, 2023 | BTIG | Buy | Maintains | $N/A | |
| May 25, 2023 | EF Hutton | Buy | Initiates | $1.75 | |
| May 18, 2023 | BTIG | Mark Massaro | Buy | Maintains | $2.00 |
| Apr 24, 2023 | BTIG | Buy | Maintains | $N/A | |
| Mar 10, 2023 | BTIG | Buy | Maintains | $N/A | |
| Feb 6, 2023 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $9.00 |
| Feb 5, 2023 | BTIG | Buy | Maintains | $N/A | |
| Jan 5, 2023 | Scotiabank | Sung Ji Nam | Sector Outperform | Initiates | $4.00 |
Bionano Genomics Inc. (BNGO) Competitors
The following stocks are similar to BioNano based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bionano Genomics Inc. (BNGO) Financial Data
Bionano Genomics Inc. has a market capitalization of $15.00M with a P/E ratio of 0.0x. The company generates $28.72M in trailing twelve-month revenue with a -134.4% profit margin.
Revenue growth is +21.3% quarter-over-quarter, while maintaining an operating margin of -115.9% and return on equity of -78.2%.
Valuation Metrics
Market Cap
$15.00M
Enterprise Value
$11.39M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.5x
Growth & Margins
Revenue Growth (YoY)
+21.3%
Gross Margin
+45.7%
Operating Margin
-115.9%
Net Margin
-134.4%
EPS Growth
+21.3%
Financial Health
Cash/Price Ratio
+136.8%
Current Ratio
2.1x
Debt/Equity
34.5x
ROE
-78.2%
ROA
-19.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bionano Genomics Inc. (BNGO) Business Model
About Bionano Genomics Inc.
What They Do
Develops advanced genomic analysis instrumentation.
Business Model
Bionano Genomics generates revenue primarily through the sale of its proprietary Saphyr system and associated consumables, which are utilized in genomic research and diagnostics. The company targets researchers and clinicians in the life sciences sector, providing them with tools to detect genetic variations that traditional methods may miss, thereby facilitating advancements in personalized medicine.
Additional Information
The Saphyr system is pivotal in identifying genetic diseases and mutations, enhancing the capabilities of genomics labs. Bionano Genomics contributes significantly to the understanding of complex genetic disorders, positioning itself as a leader in genomic medicine and improving patient outcomes through its innovative technology.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
98
CEO
Dr. Robert Erik Holmlin M.B.A., Ph.D.
Country
United States
IPO Year
N/A
Website
bionano.comBionano Genomics Inc. (BNGO) Latest News & Analysis
Latest News
Quick Summary
Bionano Laboratories, a subsidiary of Bionano Genomics (BNGO), reported a 47% increase in Medicare reimbursement rates for OGM tests in 2026, raising the payment from $1,263.53 to $1,853.22.
Why It Matters
The 47% increase in reimbursement rates for Bionano's tests indicates potential revenue growth, enhancing profitability and attractiveness to investors in the genomics sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bionano Genomics, Inc. (BNGO) will hold its Q3 2025 earnings call on November 13, 2025, at 4:30 PM EST, featuring CEO Robert Holmlin and analyst Kelly Gura.
Why It Matters
Bionano Genomics’ Q3 earnings call may reveal financial performance, strategic developments, and future guidance, directly influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Bionano Genomics (Nasdaq: BNGO) reported Q3 2025 financial results, highlighting a shift in their business model to enhance consumables and software usage among existing customers.
Why It Matters
Bionano Genomics' shift towards consumables and software suggests potential revenue growth, impacting future profitability and stock performance positively for investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bionano Genomics published a study showing that optical genome mapping (OGM) can effectively detect gene rearrangements in acute leukemias, outperforming targeted RNA-sequencing.
Why It Matters
The study validates Bionano's technology, potentially boosting its market position and attractiveness, influencing stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025
2 months ago
Quick Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) will hold a conference call and webcast on November 13, 2025, at 4:30 p.m. ET to discuss Q3 2025 financial results and corporate developments.
Why It Matters
Bionano Genomics' upcoming financial results call may impact stock performance and investor sentiment, providing insights into corporate progress and financial health.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bionano Genomics (Nasdaq: BNGO) CEO Erik Holmlin will speak at the H.C. Wainwright @ Home Event on October 15, 2025.
Why It Matters
CEO Erik Holmlin's participation in a prominent event signals potential insights into Bionano's strategy and future performance, influencing investor sentiment and stock activity.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BNGO Stock
What is Bionano Genomics Inc.'s (BNGO) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Bionano Genomics Inc. (BNGO) has a median price target of $7.50. The highest price target is $8.00 and the lowest is $7.00.
Is BNGO stock a good investment in 2026?
According to current analyst ratings, BNGO has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BNGO stock?
Wall Street analysts predict BNGO stock could reach $7.50 in the next 12 months. This represents a 383.9% increase from the current price of $1.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bionano Genomics Inc.'s business model?
Bionano Genomics generates revenue primarily through the sale of its proprietary Saphyr system and associated consumables, which are utilized in genomic research and diagnostics. The company targets researchers and clinicians in the life sciences sector, providing them with tools to detect genetic variations that traditional methods may miss, thereby facilitating advancements in personalized medicine.
What is the highest forecasted price for BNGO Bionano Genomics Inc.?
The highest price target for BNGO is $8.00 from Jason McCarthy at Maxim Group, which represents a 416.1% increase from the current price of $1.55.
What is the lowest forecasted price for BNGO Bionano Genomics Inc.?
The lowest price target for BNGO is $7.00 from Yi Chen at HC Wainwright & Co., which represents a 351.6% increase from the current price of $1.55.
What is the overall BNGO consensus from analysts for Bionano Genomics Inc.?
The overall analyst consensus for BNGO is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.50.
How accurate are BNGO stock price projections?
Stock price projections, including those for Bionano Genomics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 6:58 AM UTC